These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32024717)

  • 1. A tale of twists: loperamide-induced torsades de pointes and ventricular tachycardia storm.
    Sahu KK; El Meligy A; Mishra AK; Goyal S
    BMJ Case Rep; 2020 Feb; 13(2):. PubMed ID: 32024717
    [No Abstract]   [Full Text] [Related]  

  • 2. Self-Terminating Ventricular Fibrillation in Vandetanib-Induced Torsades de Pointes.
    Loffi M; Toffetti L; Gianni C; Lombardi F
    J Cardiovasc Electrophysiol; 2015 Jul; 26(7):811-3. PubMed ID: 25648339
    [No Abstract]   [Full Text] [Related]  

  • 3. Loperamide Induced Recurrent Torsades de Pointes: A Case Report.
    Jackson GG; Lopez CR; Bermudez ES; Hill NE; Roden DM; Ely EW; Stollings JL
    J Pharm Pract; 2022 Oct; 35(5):791-795. PubMed ID: 33779357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrocardiographic Abnormalities, Malignant Ventricular Arrhythmias, and Cardiomyopathy Associated With Loperamide Abuse.
    Vaughn P; Solik MM; Bagga S; Padanilam BJ
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1230-1233. PubMed ID: 27461785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torsades de pointes with high-dose loperamide.
    Kozak PM; Harris AE; McPherson JA; Roden DM
    J Electrocardiol; 2017; 50(3):355-357. PubMed ID: 28109524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arrhythmic storm: Short-coupled variant torsade de pointes.
    Godinho AR; Frutuoso C; Vasconcelos M; Dias P; Garcia R; Pinho T; Araújo V; Maciel MJ
    Rev Port Cardiol; 2016 May; 35(5):307.e1-5. PubMed ID: 27132471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Case Report of Loperamide-Induced Ventricular Storm.
    De Vera J; Kim HB; Sakr AE
    J Investig Med High Impact Case Rep; 2021; 9():2324709621990768. PubMed ID: 33533290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug induced QT prolongation].
    Altmann D; Eggmann U; Ammann P
    Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user.
    Atkinson D; Dunne A; Parker M
    Anaesthesia; 2007 Sep; 62(9):952-5. PubMed ID: 17697226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.
    Hoehns JD; Stanford RH; Geraets DR; Skelly KS; Lee HC; Gaul BL
    Pharmacotherapy; 2001 Jul; 21(7):871-83. PubMed ID: 11444585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Torsades de pointes ventricular tachycardia associated with overdose of astemizole.
    Rao KA; Adlakha A; Verma-Ansil B; Meloy TD; Stanton MS
    Mayo Clin Proc; 1994 Jun; 69(6):589-93. PubMed ID: 8189766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic and cardiac electrophysiological effects of SZV-270, a novel compound with combined Class I/B and Class III effects, in rabbits and dogs.
    Varga RS; Hornyik T; Husti Z; Kohajda Z; Krajsovszky G; Nagy N; Jost N; Virág L; Tálosi L; Mátyus P; Varró A; Baczkó I
    Can J Physiol Pharmacol; 2021 Jan; 99(1):89-101. PubMed ID: 32970956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loperamide-induced cardiotoxicity: a case overlooked?
    Iqbal S; Fayyaz SM; Saeed Y; Aqeel M
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day).
    Goodnough R; Nomura M; Badea A; Lynch KL; Benowitz NL; Tsutaoka B
    Clin Toxicol (Phila); 2019 Nov; 57(11):1123-1124. PubMed ID: 30777457
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ventricular Tachycardias: Characteristics and Management.
    Baldzizhar A; Manuylova E; Marchenko R; Kryvalap Y; Carey MG
    Crit Care Nurs Clin North Am; 2016 Sep; 28(3):317-29. PubMed ID: 27484660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P; Ciliberti D; Blasi N; Capone P
    Minerva Cardioangiol; 1992 Jun; 40(6):245-9. PubMed ID: 1407620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Torsade de pointes following repeated massive loperamide ingestions].
    Myllymäki L; Westerbergh J; Carlsson H; Höjer J
    Lakartidningen; 2020 Jan; 117():. PubMed ID: 32016923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient.
    Ünal Yüksekgönül A; Ertuğrul İ; Karagöz T
    Cardiol Young; 2021 Dec; 31(12):2035-2037. PubMed ID: 34024302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.